intravenous BPH therapy and fewer on oral therapy [1].
Although isolated reports of osteomalacic changes in the
treatment of Paget’s disease and osteopetrotic-like changes
in the treatment of osteogenesis imperfecta have been published
[19], most attention has been focused on concerns of
potential altered or suppressed bone turnover. Al-Muderis et al.
reported unusual metaphyseal banding termed “zebra lines” in
children treated with cyclical pamidronate for a wide range of
pediatric osteopenic disorders [20]. Suppressed bone turnover
during alendronate therapy for high-turnover osteoporosis has
been well documented [